Haohai Biotech announced that on September 2, 2026, the company repurchased 9100 H shares through the Hong Kong Stock Exchange. The repurchase price range for each share was HK$16.63 to HK$16.68, with a total cost of HK$151,600, and the repurchased shares were to be cancelled. The repurchased shares accounted for 0.004% of the total number of H shares issued on the day the repurchase authorization resolution was passed. The company's repurchase authorization was approved on May 29, 2026. The maximum number of H shares that can be repurchased is 3.478 million shares. Up to now, 652,500 shares have been repurchased, accounting for 1.88% of the authorized limit. Matters such as issuing new shares after the repurchase will be suspended until October 2, 2026.

Haohai Biotech announced that on September 2, 2026, the company repurchased 9100 H shares through the Hong Kong Stock Exchange. The repurchase price range for each share was HK$16.63 to HK$16.68, with a total cost of HK$151,600, and the repurchased shares were to be cancelled. The repurchased shares accounted for 0.004% of the total number of H shares issued on the day the repurchase authorization resolution was passed. The company's repurchase authorization was approved on May 29, 2026. The maximum number of H shares that can be repurchased is 3.478 million shares. Up to now, 652,500 shares have been repurchased, accounting for 1.88% of the authorized limit. Matters such as issuing new shares after the repurchase will be suspended until October 2, 2026.